Finasteride vs Spironolactone: Long-Term Durability of Response

How Each Drug Works Against Androgens

Finasteride inhibits 5-alpha-reductase type II, the enzyme that converts testosterone to dihydrotestosterone (DHT). At 1 mg daily, it reduces serum DHT by roughly 60-70% within two weeks of starting treatment, according to the original pharmacokinetic studies submitted to the FDA [1]. Spironolactone works differently. It competes directly with DHT at the androgen receptor and also reduces adrenal androgen output, producing a dual blockade that is particularly useful when adrenal androgens drive acne or hair thinning [2].

Why Mechanism Shapes Durability

Because finasteride acts upstream (reducing DHT production), its effect is tightly linked to continued enzyme inhibition. Stop the drug, and DHT rebounds to near-baseline levels within 14 days [1]. Spironolactone's receptor-level blockade means the drug must be present continuously to prevent DHT from activating follicles or sebaceous glands. The durability question, then, is not which drug works longer in isolation, neither works after discontinuation, but which produces more sustained benefit during continuous use and whether benefit accumulates over years.

The 5-Alpha-Reductase Isoform Distinction

Finasteride blocks type II 5-alpha-reductase selectively. Dutasteride blocks both type I and type II, but finasteride's selectivity is clinically relevant because scalp follicles express predominantly type II [3]. Spironolactone does not reduce DHT synthesis at all; it only prevents DHT from binding its receptor. This means that in a patient with very high baseline DHT, spironolactone's receptor blockade may be partially overcome at high androgen loads, which is one reason some clinicians add a low-dose 5-alpha-reductase inhibitor when spironolactone alone is insufficient.

Long-Term Evidence for Finasteride

The most rigorous long-term data for finasteride in androgenic alopecia comes from Kaufman et al. (J Am Acad Dermatol 1998), a 5-year randomized controlled trial in 523 men with vertex hair loss [4]. At year 5, 48% of men on finasteride 1 mg daily had increased hair count from baseline, and 42% maintained their baseline count. In the placebo group, 100% of participants lost hair relative to their own baseline. That 90% maintenance or improvement rate at 5 years is the benchmark against which all competing treatments are measured.

What Happens at Year 2 vs. Year 5

Hair count on finasteride typically peaks between 12 and 24 months, then stabilizes or modestly declines from that peak while remaining above baseline [4]. The Kaufman trial documented a mean increase of 277 hairs per square centimeter at 1 year, which partially attenuated to 225 hairs per square centimeter at year 5, still meaningfully above the baseline and far above the placebo group's progressive decline. The practical message: finasteride does not maintain its year-1 peak forever, but it reliably prevents the hair-count trajectory that would have occurred without treatment.

Relapse Kinetics After Stopping Finasteride

A subset analysis from the Kaufman trial showed that men who discontinued finasteride after 1 year returned to pre-treatment hair counts within 12 months [4]. Serum DHT rebounds to pre-treatment levels within two weeks of the last dose [1]. This rapid reversal is clinically important: it means that any break in therapy longer than a few weeks begins eroding the accumulated benefit. Patients who miss doses intermittently over months may see partial relapse even without fully stopping.

Long-Term Evidence for Spironolactone

Spironolactone is not FDA-approved for acne or hair loss, so its evidence base is built from observational studies and smaller controlled trials rather than the large multi-year RCTs that exist for finasteride [5]. Layton et al. (Br J Dermatol 2017) reviewed the real-world durability of spironolactone for acne in a cohort of women and found that 85% of patients maintained a clinically meaningful response (defined as greater than 50% reduction in lesion count) after 24 months of continuous use at doses between 50 mg and 200 mg daily [6].

Dose-Response Relationship Over Time

The Layton review noted that lower doses (25-50 mg/day) produced adequate initial response in mild-to-moderate acne but that durable suppression over 2 or more years was more consistently achieved at 100 mg/day or above [6]. Women who titrated up to 100-200 mg showed relapse rates under 15% at 24 months. Those maintained at 25-50 mg had relapse rates closer to 30% over the same window. This dose-durability gradient has direct clinical relevance when choosing a starting dose for a patient expecting long-term treatment.

Spironolactone for Female Pattern Hair Loss

Evidence for spironolactone in female pattern hair loss (FPHL) is less strong than for acne. A systematic review published in JAMA Dermatology 2019 identified only three randomized trials of adequate quality examining spironolactone for FPHL, with follow-up periods of 6 to 12 months [5]. Hair density improvements were statistically significant (P<0.05) but modest compared to finasteride 1-5 mg in women. Real-world series suggest that women who respond in the first 12 months tend to maintain that response for 3 or more years, but formal 5-year data comparable to the Kaufman finasteride trial do not yet exist for spironolactone in FPHL.

Relapse Kinetics After Stopping Spironolactone

Acne relapse after stopping spironolactone typically appears within 3-6 months, corresponding to the time needed for sebum production to return to androgen-stimulated baseline levels [6]. Hair shedding after stopping spironolactone follows a similar 3-6 month lag. This slightly longer rebound window (compared to finasteride's 2-week DHT rebound) may reflect the receptor-level mechanism: once spironolactone is cleared, the androgen receptors must re-accumulate sufficient stimulation before clinical changes become visible.

Direct Comparison: Durability by Indication

Neither drug has been compared head-to-head in a powered long-term randomized trial. The comparison below draws on the best available separate trial data.

| Parameter | Finasteride 1 mg | Spironolactone 50-200 mg | |---|---|---| | Primary population studied | Men, androgenic alopecia | Women, acne or FPHL | | Longest RCT follow-up | 5 years (Kaufman 1998) | 24 months (Layton 2017 review) | | % maintaining response at 2 years | ~90% hair count maintenance | ~85% acne response | | Time to relapse after stopping | 6-12 months (hair visible) | 3-6 months (acne); 3-6 months (hair) | | DHT suppression | 60-70% reduction | None (receptor blockade only) | | Pregnancy risk | Teratogenic in male fetuses | Feminization of male fetus | | Monitoring required | PSA (men >40), liver function if concerned | Potassium, blood pressure, renal function |

The most striking difference is the depth of evidence. Finasteride's 5-year RCT gives a statistically rigorous durability estimate; spironolactone's durability is inferred largely from observational series and shorter trials [4][6]. That evidence gap should inform clinical decision-making, not the assumption that shorter follow-up means shorter duration of benefit.

Who Gets Which Drug and Why

Men with Androgenic Alopecia

Finasteride 1 mg daily is the standard first-line oral option for men with androgenic alopecia, supported by FDA approval and the 5-year Kaufman dataset [4]. Spironolactone is not used in men at standard anti-androgen doses because the doses needed for meaningful DHT-receptor blockade (100-200 mg) produce gynecomastia and sexual side effects in a high proportion of male patients. A 2019 review in Dermatologic Therapy estimated gynecomastia rates of 6-10% in men on spironolactone 100 mg for acne, versus less than 1% for finasteride 1 mg [7].

Women with Acne

Spironolactone 50-200 mg is first-line anti-androgen therapy for women with hormonal acne in most dermatology guidelines. The American Academy of Dermatology 2016 acne guidelines state: "Spironolactone is a reasonable treatment option for women with acne who have not responded adequately to other therapies or who have signs of hyperandrogenism" [8]. Finasteride is used off-label in some women with severe androgenic acne, but its teratogenicity (FDA Pregnancy Category X) makes it a second-line choice requiring confirmed and reliable contraception [1].

Women with Female Pattern Hair Loss

Both drugs are used off-label in women with FPHL. Finasteride at 2.5-5 mg daily (higher than the 1 mg male dose) has shown statistically significant hair density improvements in postmenopausal women in small trials. Spironolactone 100-200 mg is preferred in premenopausal women partly because of a more tolerable safety profile when contraception is reliably in place. The endocrine.org clinical practice guidelines for FPHL note that no head-to-head trial has established superiority of either agent in women [9].

Switching from Finasteride to Spironolactone

When to Consider Switching

Switching is most common in three scenarios: a woman who was prescribed finasteride off-label for FPHL and is now planning pregnancy (finasteride must stop; spironolactone also must stop, but the decision to switch before stopping both is relevant), a patient with finasteride-related sexual side effects seeking an alternative mechanism, or a woman whose acne has emerged or worsened while on finasteride and whose dermatologist wants a drug that addresses sebaceous gland activity more directly [6][9].

How to Switch Safely

There is no validated cross-tapering protocol in the published literature. Based on the pharmacokinetics of both drugs, a practical approach used in practice is to start spironolactone at 50 mg daily during the last two weeks of finasteride use, then discontinue finasteride. This overlapping window reduces the gap in DHT-receptor blockade while finasteride's 5-alpha-reductase inhibition is clearing. Patients should expect 3-6 months before spironolactone reaches its full clinical effect on hair or skin, and some shed or acne flare during the transition period is possible [6].

What to Tell Patients About Transition Shed

A transient increase in hair shedding in the weeks after stopping finasteride is expected, because DHT rebounds within 14 days and the follicles that were in an extended anagen phase under DHT suppression may enter telogen simultaneously [4]. Spironolactone's receptor blockade begins immediately but takes weeks to months to translate into measurable hair density change. Counseling patients about this window prevents premature discontinuation of the new regimen.

Side Effects That Affect Long-Term Continuation

Durability of response is not just a pharmacological question. It depends on whether patients stay on the drug long enough to accumulate benefit. The most common reason patients stop finasteride is sexual side effects: decreased libido, erectile dysfunction, and reduced ejaculate volume, reported in approximately 3.8% of men in the original FDA trials but reported at higher rates (up to 15-20%) in patient registries and post-marketing surveys [1][10]. A 2020 analysis in JAMA Network Open found that persistent sexual dysfunction after finasteride discontinuation (sometimes called post-finasteride syndrome) was reported by 1.4% of users in a large Swedish registry [10].

Spironolactone's discontinuation driver in women is most often menstrual irregularity (affecting 22% of users in one observational series) and breast tenderness [6]. Hyperkalemia is a serious but uncommon event in otherwise healthy young women without renal disease; a 2015 study in JAMA Dermatology found clinically significant hyperkalemia in fewer than 0.5% of healthy women under 45 taking spironolactone for acne, leading the authors to suggest routine potassium monitoring may not be necessary in low-risk patients [11]. That finding has influenced practice but has not been adopted universally.

Hormonal Monitoring During Long-Term Therapy

Finasteride Monitoring

Men over 40 starting finasteride should have a baseline PSA measured, because finasteride reduces PSA by approximately 50% and can mask prostate cancer detection if the baseline is unknown [1]. The FDA label specifies that a PSA measured after 6 months of finasteride use should be doubled to estimate the true PSA level. Annual PSA review is reasonable in men over 50 on long-term finasteride therapy.

Spironolactone Monitoring

The standard monitoring protocol for spironolactone includes serum potassium and creatinine at baseline, then at 4-6 weeks after initiation or any dose increase, and annually thereafter in stable patients without renal disease [8]. Blood pressure should be checked at each visit because spironolactone's mineralocorticoid antagonism can produce orthostatic hypotension, particularly at doses above 100 mg. Women of reproductive age must use reliable contraception; a pregnancy test before starting and periodic confirmation during treatment is consistent with most institutional protocols [9].

Practical Clinical Decision Framework

Selecting between finasteride and spironolactone for long-term use comes down to four variables: patient sex, indication (hair vs. Acne vs. Both), reproductive status, and tolerability history.

Men: Finasteride 1 mg. No alternative oral anti-androgen has comparable long-term RCT data, and spironolactone's side-effect burden at effective doses makes it unsuitable for most men [4][7].

Women with acne, premenopausal: Spironolactone 100 mg starting dose, with titration to 150-200 mg if response is inadequate at 3 months. Reliable contraception required [8].

Women with FPHL, postmenopausal: Either finasteride 2.5-5 mg or spironolactone 100-200 mg is reasonable. Finasteride carries no pregnancy concern post-menopause. Spironolactone may be preferred if blood pressure control is also a therapeutic goal [9].

Women with both acne and FPHL: Spironolactone addresses both via receptor blockade and sebaceous gland suppression. Adding topical minoxidil (5% foam once daily) for hair density is the most common combination used in practice.